Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3184 - Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts)


28 Sep 2019


Poster Display session 1


Tumour Site

Soft Tissue Sarcomas


Nicolas Penel


Annals of Oncology (2019) 30 (suppl_5): v683-v709. 10.1093/annonc/mdz283


N. Penel1, J. Blay2, J. Wallet3, O. Mir4, A. Italiano5, F. Bertucci6, S. Piperno-Neumann7, T. Brodowicz8, E. Bompas9, B. Liegl-Atzwanger10, C.M. Chevreau11, I.L. Ray-Coquard12, S. Taieb13, E. Decoupigny14, M.C. Le Deley14, A. Le Cesne4

Author affiliations

  • 1 General Oncology Department, Centre Oscar Lambret, 59020 - Lille/FR
  • 2 Medicine, Centre Léon Bérard, 69008 - Lyon/FR
  • 3 Biostatistics, Centre Oscar Lambret, 59020 - Lille/FR
  • 4 Département De Médecine Oncologique, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 5 Early Phase Trials Unit, Institute Bergonié, 33076 - Bordeaux/FR
  • 6 Medical Oncology, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 7 Medical Oncology, Institut Curie, 75005 - Paris/FR
  • 8 Internal Medicine 1 - Oncology, Vienna General Hospital (AKH) - Medizinische Universität Wien, 1090 - Vienna/AT
  • 9 Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 10 Medical Oncology, Medical University of Graz, 8036 - Graz/AT
  • 11 Medical Oncology, Institut Universitaire du Cancer -Toulouse- Oncopole, 31059 - Toulouse/FR
  • 12 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 13 Radiology, Centre Oscar Lambret, 59020 - Lille/FR
  • 14 Clinical Research And Methodological Platform, Centre Oscar Lambret, 59020 - Lille/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3184


REG is an active drug in non-adipocytic soft tissue sarcoma previously treated with doxorubicin (Mir et al. Lancet Oncol 2016). Efficacy of REG in PAZ pretreated pts is unknown. REGOSARC is a multi-cohort double-blind placebo (PLAC)-controlled phase II trial assessing the activity of REG in soft-tissue sarcoma previously treated with doxorubicin. Cross-over after centrally confirmed disease progression was allowed.


In the present subgroup analyses of the pooled study (cohorts B,C,D and E), we analyzed the magnitude of REG activity in pts with prior exposure to PAZ.


The total study population consisted of 176 pts (101 women, 57%), with a median age of 59 (20-81). with the following histologies (n/%): leiomyosarcoma (80/45), synovial sarcoma (28/16) or other sarcoma (68/39). Most pts had PS = 0 (N = 83, 47%) or PS = 1 (N = 92, 52%). Median time from initial diagnosis to study enrollment was 30 months (range, 5.6-498). Median follow-up was 59.6 months. 88 pts each were allocated to the REG and placebo (PLAC) arms, including 21 (24%) and 22 (25%) pts with previous PAZ exposure. Overall, the significant benefit of REG compared to PLAC in terms of PFS with a median PFS of 3.8 (REG) vs 1.0 months (PLAC); HR(REG/PLAC)=0.43 [95%CI: 0.32-0.59], p<.00001, was confirmed. The magnitude of the benefit did not significantly differ when assessed by prior PAZ exposure: HR(REG/PLAC)=0.33 [0.18-0.61] for those previously exposed to PAZ and 0.45 [0.32-0.65] for those not exposed to PAZ; interaction test in Cox model, p = 0.35. In the total study population non significant numerically higher median OS was observed in the REG arm:13.4 (REG) vs 9.0 months (PLAC), HR = 0.76 [0.56-1.03], p = 0.08. The magnitude of this difference was larger in pts previously exposed to PAZ: HR(REG/PLAC)=0.43 [0.22-0.85] (p = 0.015), vs HR = 0.88 [0.62-1.25] (p = 0.49) for those not exposed to PAZ; interaction test, p = 0.065. Safety has been previously reported (Mir et al. Lancet Oncol 2016; Penel ASCO 2019).


We conclude that prior exposure to PAZ did not significantly modify PFS advantage of REG. Benefit of REG in terms of OS could be larger in patients previously exposed to PAZ.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Centre Oscar Lambret, Lille, France.




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.